Kjersti Flatmark
Position: Group leader, MD PhD
Phone: +47 22 78 18 63 / +47 91 16 84 66
Email:
 

Author network for Kjersti Flatmark by COREMINE medical


Publications 2016

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
Cancer Med, 5 (8), 1840-9
PubMed 27273130

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
Clin Oncol (R Coll Radiol), 28 (8), 532-9
PubMed 26888115

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
Expression and clinical significance of Wee1 in colorectal cancer
Tumour Biol, 37 (9), 12133-12140
PubMed 27220319

Flatmark K, Høye E, Fromm B (2016)
microRNAs as cancer biomarkers
Scand J Clin Lab Invest Suppl, 245, S80-3
PubMed 27542003

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Radiother Oncol, 119 (3), 505-11
PubMed 26968754

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
Clin Exp Metastasis, 34 (1), 51-62
PubMed 27812769

Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K (2016)
Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort
J Surg Oncol, 114 (2), 222-7
PubMed 27173150

Goscinski MA, Hole KH, Tønne E, Ryder T, Grøholt KK, Flatmark K (2016)
Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report
World J Surg Oncol, 14, 63
PubMed 26940557

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
Br J Cancer, 115 (8), 929-939
PubMed 27599042

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
BMC Cancer, 16, 536
PubMed 27461255

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
Cancer Res Treat (in press)
PubMed 27488871

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
Oncotarget, 7 (23), 34907-17
PubMed 27145458

Thorgersen EB, Goscinski MA, Spasojevic M, Solbakken AM, Mariathasan AB, Boye K, Larsen SG, Flatmark K (2016)
Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer
Ann Surg Oncol, 24 (3), 721-728
PubMed 27766561

Publications 2015

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
Clin Exp Metastasis, 32 (8), 755-67
PubMed 26349943

Fretland ÅA, Kazaryan AM, Bjørnbeth BA, Flatmark K, Andersen MH, Tønnessen TI, Bjørnelv GM, Fagerland MW, Kristiansen R, Øyri K, Edwin B (2015)
Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial
Trials, 16, 73
PubMed 25872027

Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, Newcomb JM, Sempere LF, Flatmark K, Hovig E, Peterson KJ (2015)
A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome
Annu Rev Genet, 49, 213-42
PubMed 26473382

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
BMC Cancer, 15, 543
PubMed 26205955

Hektoen HH, Ree AH, Redalen KR, Flatmark K (2015)
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells
J Enzyme Inhib Med Chem, 31 (5), 779-86
PubMed 26244271

Lambrecht JR, Larsen SG, Reiertsen O, Vaktskjold A, Julsrud L, Flatmark K (2015)
Prophylactic mesh at end-colostomy construction reduces parastomal hernia rate: a randomized trial
Colorectal Dis, 17 (10), O191-7
PubMed 26179984

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T (2015)
High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
Radiother Oncol, 118 (2), 393-8
PubMed 26705680

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR (2015)
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies
Crit Rev Oncol Hematol, 95 (1), 114-24
PubMed 25624177

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR (2015)
MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
Br J Radiol, 88 (1051), 20150097
PubMed 25899892

Publications 2014

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
Eur J Cancer, 51 (1), 9-17
PubMed 25466510

Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø (2014)
B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome
BMC Cancer, 14, 602
PubMed 25139714

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL et al. (2014)
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
J Enzyme Inhib Med Chem, 30 (5), 689-721
PubMed 25347767

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E (2014)
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
Int J Mol Sci, 15 (12), 22835-56
PubMed 25501337

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K (2014)
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
PLoS One, 9 (2), e89750
PubMed 24587009

Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y (2014)
The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
J Ovarian Res, 7, 23
PubMed 24528603

Publications 2013

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
PubMed 23494569

Friedman R, Boye K, Flatmark K (2013)
Molecular modelling and simulations in cancer research
Biochim Biophys Acta, 1836 (1), 1-14
PubMed 23416097

Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
Nuclear legumain activity in colorectal cancer
PLoS One, 8 (1), e52980
PubMed 23326369

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
Int J Radiat Oncol Biol Phys, 87 (4), 753-60
PubMed 24035332

Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
Clinical significance of disseminated tumour cells in non-small cell lung cancer
Br J Cancer, 109 (5), 1264-70
PubMed 23942067

Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K (2013)
Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer
PLoS One, 8 (6), e66165
PubMed 23824282

Sørensen O, Andersen AM, Kristian A, Giercksky KE, Flatmark K (2013)
Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis
J Surg Oncol, 109 (6), 521-6
PubMed 24347444

Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J (2013)
Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer
Clin Colorectal Cancer, 12 (4), 261-6
PubMed 24012455

Publications 2012

Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K (2012)
EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
Br J Cancer, 107 (4), 667-74
PubMed 22782346

Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B (2012)
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
Virchows Arch, 460 (2), 193-202
PubMed 22249560

Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O (2012)
B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer
Int J Cancer, 131 (11), 2528-36
PubMed 22473715

Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
PLoS One, 7 (11), e50806
PubMed 23226389

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
Radiat Oncol, 7, 165
PubMed 23017053

Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K (2012)
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
BMC Cancer, 12, 505
PubMed 23121918

Schee K, Flatmark K, Holm R, Boye K, Paus E (2012)
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients (vol 33, pg 73, 2012)
Tumor Biol., 33 (4), 1263-1264

Sørensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky KE, Larsen SG (2012)
Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei
Eur J Surg Oncol, 38 (10), 969-76
PubMed 22763244

Publications 2011

Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011)
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
Radiat Oncol, 6, 33
PubMed 21473790

Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Hårklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad Ø (2011)
Disseminated tumour cells as a prognostic biomarker in colorectal cancer
Br J Cancer, 104 (9), 1434-9
PubMed 21448171

Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH (2011)
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
Angiogenesis, 14 (4), 481-9
PubMed 21833622

Schee K, Flatmark K, Holm R, Boye K, Paus E (2011)
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients
Tumour Biol, 33 (1), 73-83
PubMed 22006279

Wiig JN, Larsen SG, Dueland S, Flatmark K, Giercksky KE (2011)
Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome
Colorectal Dis, 13 (5), 506-11
PubMed 20236148

Publications 2010

Berge G, Costea DE, Berg M, Rasmussen H, Grotterød I, Lothe RA, Mælandsmo GM, Flatmark K (2010)
Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma
Amino Acids, 41 (4), 875-84
PubMed 20191297

Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010)
Nuclear S100A4 is a novel prognostic marker in colorectal cancer
Eur J Cancer, 46 (16), 2919-25
PubMed 20719498

Flatmark K, Davidson B, Kristian A, Stavnes HT, Førsund M, Reed W (2010)
Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
Hum Pathol, 41 (8), 1109-19
PubMed 20338618

Flatmark K, Ree AH (2010)
Radiosensitizing drugs: lessons to be learned from the oxaliplatin story
J Clin Oncol, 28 (29), e577-8; author reply e581-3
PubMed 20733124

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
Int J Radiat Oncol Biol Phys, 78 (2), 555-62
PubMed 20675069

Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
Tumour Biol, 32 (1), 1-12
PubMed 20652782

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
Lancet Oncol, 11 (5), 459-64
PubMed 20378407

Schee K, Fodstad Ø, Flatmark K (2010)
MicroRNAs as biomarkers in colorectal cancer
Am J Pathol, 177 (4), 1592-9
PubMed 20829435

Sørensen O, Andersen A, Olsen H, Alexandr K, Ekstrøm PO, Giercksky KE, Flatmark K (2010)
Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study
BMC Cancer, 10, 469
PubMed 20809961

Publications 2009

Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K (2009)
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
Int J Radiat Oncol Biol Phys, 74 (2), 546-52
PubMed 19427556

Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
Tumour Biol, 30 (1), 15-25
PubMed 19194111

Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E (2009)
MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
Radiother Oncol, 93 (2), 279-84
PubMed 19800704

Publications 2008

Brunsvig PF, Flatmark K, Aamdal S, Høifødt H, Le H, Jakobsen E, Sandstad B, Fodstad O (2008)
Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
Lung Cancer, 61 (2), 170-6
PubMed 18261824

Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
BMC Cancer, 8, 172
PubMed 18554396

Ree AH, Folkvord S, Flatmark K (2008)
HDAC2 deficiency and histone acetylation
Nat Genet, 40 (7), 812-3; author reply 813
PubMed 18583969

Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF (2008)
Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy
Mol Cancer, 7, 33
PubMed 18439252

Publications 2007

Flatmark K, Reed W, Halvorsen T, Sørensen O, Wiig JN, Larsen SG, Fodstad Ø, Giercksky KE (2007)
Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype
BMC Cancer, 7, 116
PubMed 17603904

Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH (2007)
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
Radiother Oncol, 86 (3), 428-34
PubMed 18006097

Seierstad T, Folkvord S, Røe K, Flatmark K, Skretting A, Olsen DR (2007)
Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice
Neoplasia, 9 (5), 392-400
PubMed 17534444

Publications 2006

Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH (2006)
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
Radiat Oncol, 1, 25
PubMed 16887021

Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
Anticancer Res, 26 (3A), 1909-16
PubMed 16827124

Publications 2005

Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM (2005)
Matrix metalloproteinases participate in osteosarcoma invasion
J Surg Res, 127 (2), 151-6
PubMed 16083752

Publications 2004

Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø (2004)
Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice
Eur J Cancer, 40 (10), 1593-8
PubMed 15196545

Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad Ø, Paus E (2004)
Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum
Tumour Biol, 25 (1-2), 31-40
PubMed 15192310

Publications 2003

Bjørnland K, Flatmark K, Mala T, Mathisen O, Bakka A, Aasen AO, Bergan A, Søreide O, Fodstad O (2003)
Detection of disseminated tumour cells in bone marrow of patients with isolated liver metastases from colorectal cancer
J Surg Oncol, 82 (4), 224-7
PubMed 12672004

Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, Bjørnland K, Fodstad Ø, Maelandsmo GM (2003)
Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer
J Pathol, 200 (5), 589-95
PubMed 12898594

Publications 2002

Flatmark K, Bjørnland K, Johannessen HO, Hegstad E, Rosales R, Hårklau L, Solhaug JH, Faye RS, Søreide O, Fodstad Ø, Study Group for Micrometastases in BM in Colorectal Cancer (2002)
Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients
Clin Cancer Res, 8 (2), 444-9
PubMed 11839662

Publications 2000

Flatmark K, Nilsen BH (2000)
[Postoperative wound infections in elective colorectal surgery]
Tidsskr Nor Laegeforen, 120 (23), 2761-3
PubMed 11107920